MIL62
As of the edition of 20 October 2026, MIL62 is a drug known only by a code name: in active development; acts on MS4A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 5, 0 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Eye; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MS4A1 | B-lymphocyte antigen CD20 | P11836 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 3 | 0 | 3 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Mabworks Biotech | Lead sponsor of trials | 2022 to now |